Journals / Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi / 2021 / Cilt: 25 - Sayı: 3

Molecular Docking Analysis of Used Drugs for the Treatment of Cancer

Kanser Tedavisinde Kullanılan İlaçların Moleküler Kenetlenme Analizi

Pages
539–547
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Furthermore, the pharmacophoric features of the investigated molecules were determined.The aim of the work is to deeply investigate the binding properties of the title drugs with DNA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, the lowest energy molecular structures were determined by conformational analysis of six drugs commonly used in cancer treatment, in order to use as initial data for docking simulations.
📊
Key Findings & Data:Using the AutoDock Vina software, the interaction mechanisms of the 6 FDA approved drugs (Pemetrexed, Irinotecan, Tamoxifen, Gemcitabine, Topotecan and Temozolomide) with DNA were investigated.
💡
Conclusion & Impact:Furthermore, the pharmacophoric features of the investigated molecules were determined.The aim of the work is to deeply investigate the binding properties of the title drugs with DNA.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Kanser · İlaçlar · Moleküler modelleme

Abstract

In this study, the lowest energy molecular structures were determined by conformational analysis of six drugs commonly used in cancer treatment, in order to use as initial data for docking simulations. Using the AutoDock Vina software, the interaction mechanisms of the 6 FDA approved drugs (Pemetrexed, Irinotecan, Tamoxifen, Gemcitabine, Topotecan and Temozolomide) with DNA were investigated. In addition, MM/PB(GB)SA calculations for the drug-DNA structures under investigation have been performed. The calculated binding affinities and binding free energies of interactions were showed the stability of the structures. It has been found that the active site where these molecules interact with DNA is the same and that their various interactions, primarily hydrogen bond, play an important role in this stability of the structures. Furthermore, the pharmacophoric features of the investigated molecules were determined.The aim of the work is to deeply investigate the binding properties of the title drugs with DNA.

Özet

Bu çalışmada, kenetlenme simülasyonları için başlangıç verileri olarak kullanılmak üzere, kanser tedavisinde yaygın olarak kullanılan altı ilacın konformasyonel analizi ile en düşük enerjili moleküler yapıları belirlenmiştir. AutoDock Vina programı kullanılarak FDA onaylı 6 ilacın (Pemetrekset, Irinotekan, Tamoksifen, Gemsitabin, Topotekan ve Temozolomid) DNA ile etkileşim mekanizmaları araştırılmıştır. Ek olarak, araştırılan ilaç-DNA yapıları için MM/PB(GB)SA hesaplamaları yapılmıştır. Etkileşimlere ait hesaplanan bağlanma afiniteleri ve bağlanma serbest enerjileri yapıların kararlılığını göstermiştir. Bu moleküllerin DNA ile etkileştiği aktif bölgenin aynı olduğu ve başta hidrojen bağı olmak üzere yapmış oldukları çeşitli etkileşimlerin yapıların bu kararlılığında önemli bir rol oynadığı bulunmuştur. Ayrıca, incelenen moleküllerin farmokofor özellikleri belirlenmiştir. Bu çalışmanın amacı, başlıktaki ilaçların DNA ile bağlanma özelliklerini derinlemesine araştırmaktır.

🔖

Cite This Article

DEMİRAG, A. D., ÇELİK, S., AKYÜZ, S., ÖZEL, A. (2021). Molecular Docking Analysis of Used Drugs for the Treatment of Cancer. Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi, Cilt: 25 - Sayı: 3, 539–547. https://ajindex.com/articles/397387

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Robson, M., Storm, C., Weitzel, J., Wollins, D., Offit, K. 2010. American society of clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. Journal of Clinical Oncology, 25(8), 893- 901
  2. Demirelli, F. 2003. Kanserin moleküler temelleri. Güncel Klinik Onkoloji, 9-15
  3. Rieger, P. 2006. Cancer biology and implications for practice. Clinical Journal of Oncology Nurisng, 10(4), 457-460
  4. Hahn, W., Weinberg, R. 2002. Mechanisms of disease: rules for making human tumor cells. New England Journal of Medicine, 347, 1593-1603
  5. Lewin, B. 1997. Genes VI. Oxford University Press, New York, USA, 1089-129
  6. Schilsky, R.L. 1992. Antimetabolites. In: Perry MC, ed. The Chemotherapy Source Book. Baltimore, MD: Williams & Wilkin, 301-315
  7. Baykara, O. 2015. Current Therapies and Latest Developments in Cancer Treatment. Horizons in Cancer Research, 57, 105-156
  8. Mian, M., Tinelli, M., De March, E., Turri, G., Meneghini, V., Pescosta, N.,. & Pizzolo, G. 2016. Bortezomib, thalidomide and lenalidomide: Have they really changed the outcome of multiple myeloma?. Anticancer Research, 36(3), 1059-1065
  9. Yang, I. A., Shaw, J. G., Goddard, J. R., Clarke, M. S., & Reid, D. W. 2016. Use of inhaled corticosteroids in COPD: improving efficacy. Expert Review of Respiratory Medicine, 10(3), 339-350
  10. Lee, C. H., Hyun, M. K., Jang, E. J., Lee, N. R., Kim, K., & Yim, J. J. 2013. Inhaled corticosteroid use and risks of lung cancer and laryngeal cancer. Respiratory medicine, 107(8), 1222-1233
  11. Patil, Y., Amitay, Y., Ohana, P., Shmeeda, H., & Gabizon, A. 2016. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity. Journal of Controlled Release, 225, 87-95
  12. Michalska, M., Schultze-Seemann, S., Bogatyreva, L., Hauschke, D., Wetterauer, U., & Wolf, P. 2016. In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer. Oncotarget, 7(16), 22531
  13. Olsen, I. H., Knigge, U., Federspiel, B., Hansen, C. P., Skov, A., Kjær, A., & Langer, S. W. 2014. Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomas. Journal of Cancer, 5(8), 628
  14. Taylor, E.C., Patel, H.H. 1992. Synthesis of pyrazolo(3,4,-d)pyrimidine analogues of the potent antitumor agent n-{4-(2-(2-amino-4(3h)- oxo-7h-pyrrolo(2,3- d)pyrimidin-5-yl)eth